950140 — Englewood Lab Cashflow Statement
0.000.00%
- KR₩199bn
- KR₩191bn
- $133.59m
- 47
- 50
- 46
- 45
Annual cashflow statement for Englewood Lab, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | ARS | ARS | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 2.61 | 13.1 | 5.62 | 15.9 | 14.4 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 4.38 | -0.81 | 3.33 | 7.81 | 3.77 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -4.36 | -21.7 | -4.84 | -11.1 | -12.2 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 6.71 | -5.79 | 7.54 | 16 | 9.47 |
Capital Expenditures | -3.66 | -2.09 | -3.33 | -2.02 | -3.7 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 8.5 | 0.232 | 0.039 | -3.99 | -2.03 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 4.84 | -1.86 | -3.3 | -6.01 | -5.74 |
Financing Cash Flow Items | -0.79 | 0 | — | — | — |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -6.85 | 5.8 | -2.9 | -9.82 | 7.56 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 4.74 | -1.95 | 1.27 | 0.09 | 10.3 |